Oncology News | pharmaphorum

News

Dr Dominik Schumacher, Tubulis' co-founder and chief executive

Germany's Tubulis raises €308m for ADC pipeline

Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer.

News

Can new Tukysa data drop unlock its sales potential?

A phase 3 study suggests Pfizer's underperforming HER2 inhibitor Tukysa could play a role in first-line maintenance of HER2-positive breast cancer.

News

Astellas suffers pancreatic cancer failure with Vyloy

Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.

News

Kelun gets world-first approval for TROP2 ADC

Kelun-Biotech has picked up another world-first approval for its TROP2-targeting ADC sac-TMT in non-small cell lung cancer.

News

Close up in sepia on Benjamin Franklin face on cash note

Soufflé's tasty $200m raise, and other biofinancings

New biotech financings include nine-figure rounds for Soufflé, Expedition, Arthrosi, and Nilo Therapeutics, with NanoPhoria and TORL not far behind.

News

Regeneron's Libtayo stakes out new territory in skin cancer

Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

Germany's Tubulis raises €308m for ADC pipeline

Can new Tukysa data drop unlock its sales potential?

Astellas suffers pancreatic cancer failure with Vyloy

Kelun gets world-first approval for TROP2 ADC

Soufflé's tasty $200m raise, and other biofinancings

Regeneron's Libtayo stakes out new territory in skin cancer

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks